Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Sezary Syndrome 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Hodgkin Disease 1Hematologic Neoplasms 1Cytomegalovirus Infections 1

Interventions

Cyclophosphamide 15romidepsin 9Whole-Body Irradiation 9fludarabine phosphate 8Vincristine 8Etoposide 8Doxorubicin 8Prednisone 7Peripheral Blood Stem Cell Transplantation 7Mycophenolic Acid 7Brentuximab Vedotin 610-propargyl-10-deazaaminopterin 6Rituximab 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Cyclosporine 5denileukin diftitox 4Nivolumab 4Lenalidomide 4mogamulizumab 3Tacrolimus 3Methotrexate 3Immunohistochemistry 3Gene Expression Profiling 3Dexamethasone 3Alemtuzumab 3selinexor 2pembrolizumab 2pegfilgrastim 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell, Peripheral × letermovir × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡